Market Place
Sourcing Support
All News #Library
Biotech
SELLAS Life Sciences Reveals 2025 Financials And Corporate Update
19 Mar 2026 //
GLOBENEWSWIRE
SELLAS Life Sciences Showcases Sls009`s Strong AML Activity
17 Mar 2026 //
GLOBENEWSWIRE
SELLAS Enrolls First Patient In New First-Line AML Trial
12 Mar 2026 //
GLOBENEWSWIRE
SELLAS Life Sciences Expands SLS009 Clinical Program In Europe
14 Jan 2026 //
GLOBENEWSWIRE
SELLAS Life Sciences Updates Ph 3 Trial Of Galinpepimut-S in AML
29 Dec 2025 //
GLOBENEWSWIRE
SELLAS Reveals Positive Phase 2 SLS009+AZA/VEN in R/R AML at ASH
07 Dec 2025 //
GLOBENEWSWIRE
SELLAS Presents Phase 2 Data Of SLS009 With Azacitidine
03 Nov 2025 //
GLOBENEWSWIRE
SELLAS Raises $31M via Warrant Exercise by Institutional Investor
27 Oct 2025 //
GLOBENEWSWIRE
Sellas’ CDK9 Inhibitor Tied to 50% Response Rate in AML in Ph 2
16 Jul 2025 //
FIERCE BIOTECH
Sellas Receives FDA Rare Pediatric Designation For Galinpepimut-S
15 Oct 2024 //
GLOBENEWSWIRE
SELLAS Life Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S
27 Dec 2023 //
GLOBENEWSWIRE
SELLAS Reaches Target Enrollment in Phase 3 Trial of Galinpepimut-S
29 Nov 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on CMC
13 Nov 2023 //
GLOBENEWSWIRE
SELLAS Life to Present Final Data from Phase 1/2 Study of Galinpepimut-S
17 Oct 2023 //
GLOBENEWSWIRE
SELLAS Life Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S
12 Oct 2023 //
GLOBENEWSWIRE
SELLAS Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue
22 Aug 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Reports +ve Data in Completed Ph1 Study of Galinpepimut-S
28 Jun 2023 //
GLOBENEWSWIRE
SELLAS to Host Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
19 Jan 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.